This post was originally published on this site
Under the deal, Germany’s Bayer will provide access to international pharmaceutical markets as well as its global supply chain and distribution network, the tabloid newspaper reported in an excerpt made available to Reuters ahead of publication. The report did not specify its sources.
The report did not disclose financial terms.
Bayer and CureVac were not immediately available for comment.
CureVac last month started a large Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, banking on the same technology that has allowed rivals BioNTech and Moderna (NASDAQ:MRNA) to lead the development race.
